Role of human nucleoside transporters in the cellular uptake of two inhibitors of IMP dehydrogenase, tiazofurin and benzamide riboside

Molecular Pharmacology

Volumn 67, Issue 1, 2005, Pages 273-279

  Damaraju, Vijaya L ^a,b   Visser, Frank ^a,b   Zhang, Jing ^a,b   Mowles, Delores ^a,b   Ng, Amy M L ^a   Young, James D ^a   Jayaram, Hiremagalur N ^c   Cass, Carol E ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; BENZAMIDE RIBOSIDE; CONCENTRATIVE NUCLEOSIE TRANSPORTER 1; CONCENTRATIVE NUCLEOSIE TRANSPORTER 2; CONCENTRATIVE NUCLEOSIE TRANSPORTER 3; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; INOSINATE DEHYDROGENASE; INOSINATE DEHYDROGENASE INHIBITOR; NITROBENZYLTHIOINOSINE; NUCLEOSIDE TRANSPORTER; TIAZOFURIN; UNCLASSIFIED DRUG; URIDINE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG COMPARISON; DRUG CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; DRUG UPTAKE; HUMAN; HUMAN CELL; NONHUMAN; OOCYTE TRANSPORT; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; WILD TYPE; XENOPUS LAEVIS;

ANIMALS; BIOLOGICAL TRANSPORT; CELL SURVIVAL; FEMALE; HUMANS; IMP DEHYDROGENASE; MEMBRANE TRANSPORT PROTEINS; NUCLEOSIDES; OOCYTES; PROTEIN ISOFORMS; RECOMBINANT PROTEINS; RIBAVIRIN; SACCHAROMYCES CEREVISIAE; URIDINE; XENOPUS LAEVIS;

EID: 11244273057     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.004408     Document Type: Article

References (40)

1. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, and Young JD (2004) The equilibrative nucleoside transporter family, SLC29. Pflueg Arch Eur J Physiol 447:735-743.
2. Cass CE, King KM, Montano JT, and Janowska-Wieczorek A (1992) A comparison of the abilities of nitrobenzylthioinosine, dilazep and dipyridamole to protect human hematopoietic cells from 7-deazaadenosine (tubercidin). Cancer Res 52:5879-5886.
3. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
4. Crawford CR, Patel DH, Naeve C, and Belt JA (1998) Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line. J Biol Chem 273:5288-5293.
5. Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, and Cass CE (2003) Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22:7524-7536.
6. Franchetti P and Grifantini M (1999) Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents. Curr Med Chem 6:599-614.
7. Galmarini CM, Clarke ML, Falette N, Puisieux A, Mackey JR, and Dumontet C (2002) Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer 87:439-445.
8. Galmarini CM, Voorzanger N, Falette N, Jordheim L, Cros E, Puisieux A, and Dumontet C (2003) Influence of p53 and p21(WAF1) expression on sensitivity of cancer cells to cladribine. Biochem Pharmacol 65:121-129.
9. Gharehbaghi K, Paull KD, Kelley JA, Barchi JJ Jr, Marquez VE, Cooney DA, Monks A, Scudiero D, Krohn K, and Jayaram HN (1994a) Cytotoxicity and characterization of an active metabolite of benzamide riboside, a novel inhibitor of IMP dehydrogenase. Int J Cancer 56:892-899.
10. Gharehbaghi K, Sreenath A, Hao Z, Paull KD, Szekeres T, Cooney DA, Krohn K, and Jayaram HN (1994b) Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin. Biochem Pharmacol 48:1413-1419.
11. Grifantini M (2000) Tiazofurine ICN Pharmaceuticals. Curr Opin Investig Drugs 1:257-262.
12. Griffiths M, Beaumont N, Yao SY, Sundaram M, Boumah CE, Davies A, Kwong FY, Coe I, Cass CE, Young JD, et al. (1997) Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat Med 3:89-93.
13. Grusch M, Polgar D, Gfatter S, Leuhuber K, Huettenbrenner S, Leisser C, Fuhrmann G, Kassie F, Steinkellner H, Smid K, et al. (2002) Maintenance of ATP favours apoptosis over necrosis triggered by benzamide riboside. Cell Death Differ 9:169-178.
14. Jager W, Salamon A, and Szekeres T (2002) Metabolism of the novel IMP dehydrogenase inhibitor benzamide riboside. Curr Med Chem 9:781-786.
15. Jayaram HN, Cooney DA, Grusch M, and Krupitza G (1999) Consequences of IMP dehydrogenase inhibition and its relationship to cancer and apoptosis. Curr Med Chem 6:561-574.
16. Jayaram HN, Dion RL, Glazer RI, Johns DG, Robins RK, Srivastava PC, and Cooney DA (1982) Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193). Biochem Pharmacol 31:2371-2380.
17. Jayaram HN, Lapis E, Tricot G, Kneebone P, Paulik E, Zhen W, Engeler GP, Hoffman R, and Weber G (1992) Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion. Int J Cancer 51:182-188.
18. Jayaram HN, Zhen W, and Gharehbaghi K (1993) Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells. Cancer Res 53:2344-2348.
19. Khanna N, Jayaram HN, and Singh N (2004) Benzamide riboside induced mitochondrial mediated apoptosis in human lung cancer H520 cells. Life Sci 75:179-190.
20. Knight RD, Mangum J, Lucas DL, Cooney DA, Khan EC, and Wright DG (1987) Inosine monophosphate dehydrogenase and myeloid cell maturation. Blood 69:634-639.
21. Lang TT, Selner M, Young JD, and Cass CE (2001) Acquisition of human concentrative nucleoside transporter 2 (hcnt2) activity by gene transfer confers sensitivity to fluoropyrimidine nucleosides in drug-resistant leukemia cells. Mol Pharmacol 60:1143-1152.
22. Lang TT, Young JD, and Cass CE (2004) Interactions of nucleoside analogs, caffeine and nicotine with human concentrative nucleoside transporters 1 and 2 stably produced in a transport-defective human cell line. Mol Pharmacol 65:925-933.
23. Liu Y, Bonn SA, and Sherley JL (1998) Inosine-5′-monophosphate dehydrogenase is a rate-determining factor for p53-dependent growth regulation. Mol Biol Cell 9:15-28.
24. Monks A, Marquez VE, Mao DT, and Cysyk RL (1985) Uptake of 2-beta-D-ribofuranosylthiazole-4-carboxamide (tiazofurin) and analogues by the facilitated transport mechanism of erythrocytes. Cancer Lett 28:1-8.
25. Pettitt AR, Clarke AR, Cawley JC, and Griffiths SD (1999) Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms. Br J Haematol 105:986-988.
26. Rauko P, Novotny L, Dovinova I, Hunakova L, Szekeres T, and Jayaram HN (2001) Antitumor activity of benzamide riboside and its combination with cisplatin and staurosporine. Eur J Pharm Sci 12:387-394.
27. Ritzel MW, Ng AM, Yao SY, Graham K, Loewen SK, Smith KM, Ritzel RG, Mowles DA, Carpenter P, Chen XZ, et al. (2001) Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem 276:2914-2927.
28. Ritzel MW, Yao SY, Huang MY, Elliott JF, Cass CE, and Young JD (1997) Molecular cloning and functional expression of cDNAs encoding a human Na+-nucleoside cotransporter (hCNT1). Am J Physiol 272:C707-C7014.
29. +/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol Membr Biol 15:203-211.
30. Sherley JL (1991) Guanine nucleotide biosynthesis is regulated by the cellular p53 concentration. J Biol Chem 266:24815-24828.
31. Sherley JL, Stadler PB, and Johnson DR (1995) Expression of the wild-type p53 antioncogene induces guanine nucleotide-dependent stem cell division kinetics. Proc Natl Acad Sci USA 92:136-140.
32. Soussi T, Dehouche K, and Beroud C (2000) p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat 15:105-113.
33. Stadler PB, Pennacchi J, and Sherley JL (1994) Inosine-5′- monophosphate dehydrogenase activity is maintained in immortalized murine cells growth-arrested by serum deprivation. Adv Enzyme Regul 34:91-106.
34. Tricot GJ, Jayaram HN, Lapis E, Natsumeda Y, Nichols CR, Kneebone P, Heerema N, Weber G, and Hoffman R (1989) Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5′-phosphate dehydrogenase activity. Cancer Res 49:3696-3701.
35. Ullman B, Coons T, Rockwell S, and McCartan K (1988) Genetic analysis 2′,3′-dideoxycytidine incorporation into cultured human T lymphoblasts. J Biol Chem 263:12391-12396.
36. Vickers MF, Yao SY, Baldwin SA, Young JD, and Cass CE (2000) Nucleoside transporter proteins of Saccharomyces cerevisiae. Demonstration of transporter (FUI1) with high uridine selectivity in plasma membranes and a transporter (FUN26) with broad nucleoside selectivity in intracellular membranes. J Biol Chem 275:25931-25938.
37. Visser F, Vickers MF, Ng AM, Baldwin SA, Young JD, and Cass CE (2002) Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole. J Biol Chem 277:395-401.
38. Wright DG, Boosalis MS, Waraska K, Oshry LJ, Weintraub LR, and Vosburgh E (1996) Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis. Anticancer Res 16:3349-3351.
39. Yao SY, Ng AM, Vickers MF, Sundaram M, Cass CE, Baldwin SA, and Young JD (2002) Functional and molecular characterization of nucleobase transport by recombinant human and rat equilibrative nucleoside transporters 1 and 2. Chimeric constructs reveal a role for the ENT2 helix 5-6 region in nucleobase translocation. J Biol Chem 277:24938-24948.
40. Zhang J, Visser F, Vickers MF, Lang T, Robins MJ, Nielsen LP, Nowak I, Baldwin SA, Young JD, and Cass CE (2003) Uridine binding motifs of human concentrative nucleoside transporters 1 and 3 produced in Saccharomyces cerevisiae. Mol Pharmacol 64:1512-1520.